In the Achieve-3 phase 3 trial across 131 centers in Argentina, China, Japan, Mexico, and the US, orforglipron produced average weight losses of about 6–8% versus 4–5% with oral semaglutide over a year.

Tablet-based GLP-1 therapies could be transformative due to easier use, storage, and potentially lower costs, though safety and regulatory considerations remain.

Many experts view the findings as a meaningful step forward in weight management for people with Type 2 diabetes, with potential access expansion if approved, given current NHS limits on weight loss injections.

Clinicians emphasize the need for a range of safe, effective treatments to reduce obesity-related risks and to broaden access beyond private prescriptions.

Orforglipron, a new oral GLP-1 pill from Eli Lilly, demonstrated greater weight loss and better blood sugar control than the current oral option in a Lancet trial of roughly 1,500 people with Type 2 diabetes.

At higher doses (12–36 mg), orforglipron led to 15–20 pounds of weight loss over one year, compared with 8–11 pounds for 7–14 mg Rybelsus, with additional improvements in cholesterol, blood pressure, and triglycerides.

If approved in the US, orforglipron could reach the market as soon as spring 2026, potentially priced around $300 per month, notably lower than injectable GLP-1 therapies.

Despite stronger weight loss results, questions about long-term safety, cardiovascular outcomes, and sustained effectiveness persist due to tolerability concerns and the study’s one-year duration.

The pill offers practical advantages—no fasting, no timing constraints, and no refrigeration—facilitating distribution, though higher efficacy comes with more gastrointestinal side effects and about 10% discontinuation at the highest dose versus ~5% for Rybelsus.

Experts see the trial findings as potentially shifting weight-management and diabetes care, with incretin-based therapies possibly becoming prominent first-line options in the coming decade.

Experts and industry voices caution that longer-term data and real-world adherence and tolerability will be crucial for real-world success.

Lilly has increased manufacturing capacity to meet anticipated demand, with analysts viewing orforglipron as a potential game-changer in weight management and diabetes treatment, poised to reshape the GLP-1 landscape in 2026.